© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 3, 179-181,
February 2, 2000
© 2000 Oxford University Press
EDITORIALS |
Will There Be Resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?
Affiliation of authors: Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC.
Correspondence to: E. A. Gehan, Ph.D., Lombardi Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd., N.W., Washington, DC 20007 (e-mail: gehane@gunet.georgetown.edu).
From the earliest days of the Cancer Chemotherapy Cooperative
Group Clinical Trials program in the 1950s, there have been concerns
about the definition of response in solid tumors and the reliance on
quantitative measurements. In the first clinical trial in solid tumors
published by Zubrod et al. (1), "Treatment was considered to
give a positive response if either the total measured tumor mass
decreased, with no lesions increasing in size and no new lesions
appearing . . . or the group of voting physicians considered that
the treatment had been of benefit to the patient as a
whole. . . . ." On the initiative of the World Health
Organization (WHO) and following two meetings on the standardization of
reporting results of cancer treatment in 1977 and 1979, Miller et al.
(2) proposed uniform criteria for reporting response,
recurrence, and disease-free interval and the grading of
REFERENCES
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. B. Cwikla, A. Sankowski, N. Seklecka, J. R. Buscombe, A. Nasierowska-Guttmejer, K. G. Jeziorski, R. Mikolajczak, D. Pawlak, K. Stepien, and J. Walecki Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study Ann. Onc., October 15, 2009; (2009) mdp372v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Kloos, M. D. Ringel, M. V. Knopp, N. C. Hall, M. King, R. Stevens, J. Liang, P. E. Wakely Jr, V. V. Vasko, M. Saji, et al. Phase II Trial of Sorafenib in Metastatic Thyroid Cancer J. Clin. Oncol., April 1, 2009; 27(10): 1675 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-S. Park, E. Klotz, M.-J. Kim, S. Y. Song, S. W. Park, S.-W. Cha, J. S. Lim, J. Seong, J. B. Chung, and K. W. Kim Perfusion CT: Noninvasive Surrogate Marker for Stratification of Pancreatic Cancer Response to Concurrent Chemo- and Radiation Therapy Radiology, January 1, 2009; 250(1): 110 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-S. Tham, L. Wang, R. A. Soo, S.-C. Lee, H.-S. Lee, W.-P. Yong, B.-C. Goh, and N. H.G. Holford A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non-Small Cell Lung Cancer Patients Clin. Cancer Res., July 1, 2008; 14(13): 4213 - 4218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Schuetze, L. H. Baker, R. S. Benjamin, and R. Canetta Selection of Response Criteria for Clinical Trials of Sarcoma Treatment Oncologist, April 1, 2008; 13(suppl_2): 32 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Evilevitch, W. A. Weber, W. D. Tap, M. Allen-Auerbach, K. Chow, S. D. Nelson, F. R. Eilber, J. J. Eckardt, R. M. Elashoff, M. E. Phelps, et al. Reduction of Glucose Metabolic Activity Is More Accurate than Change in Size at Predicting Histopathologic Response to Neoadjuvant Therapy in High-Grade Soft-Tissue Sarcomas Clin. Cancer Res., February 1, 2008; 14(3): 715 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N van Zandwijk, A Mathy, L Boerrigter, H Ruijter, I Tielen, D de Jong, P Baas, S Burgers, and P Nederlof EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer Ann. Onc., January 1, 2007; 18(1): 99 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Shah, S. Kesari, R. Xu, T. T. Batchelor, A. M. O'Neill, F. H. Hochberg, B. Levy, J. Bradshaw, and P. Y. Wen Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas Neuro-oncol, January 1, 2006; 8(1): 38 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. G. McStay, D. Maudgil, M. Williams, J. M. Tibballs, A. F. Watkinson, M. E. Caplin, and J. R. Buscombe Large-Volume Liver Metastases from Neuroendocrine Tumors: Hepatic Intraarterial 90Y-DOTA-Lanreotide as Effective Palliative Therapy Radiology, November 1, 2005; 237(2): 718 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Gronlund, C. Hogdall, J. Hilden, S. A. Engelholm, E. V.S. Hogdall, and H. H. Hansen Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovarian Carcinoma? J. Clin. Oncol., October 15, 2004; 22(20): 4051 - 4058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Fountzilas, H. P. Kalofonos, U. Dafni, C. Papadimitriou, D. Bafaloukos, P. Papakostas, A. Kalogera-Fountzila, H. Gogas, G. Aravantinos, L. A. Moulopoulos, et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group Ann. Onc., October 1, 2004; 15(10): 1517 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Haringhuizen, H. van Tinteren, H. F. R. Vaessen, P. Baas, and N. van Zandwijk Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients Ann. Onc., May 1, 2004; 15(5): 786 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. O. Park, S. I. Lee, S. Y. Song, K. Kim, W. S. Kim, C. W. Jung, Y. S. Park, Y.-H. Im, W. K. Kang, M. H. Lee, et al. Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria Jpn. J. Clin. Oncol., October 1, 2003; 33(10): 533 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K McHugh and S Kao Response evaluation criteria in solid tumours (RECIST): problems and need for modifications in paediatric oncology? Br. J. Radiol., July 1, 2003; 76(907): 433 - 436. [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Buscombe, M. E. Caplin, and A. J.W. Hilson Long-Term Efficacy of High-Activity 111In-Pentetreotide Therapy in Patients with Disseminated Neuroendocrine Tumors J. Nucl. Med., January 1, 2003; 44(1): 1 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Warren, N. Patronas, A. A. Aikin, P. S. Albert, and F. M. Balis Comparison of One-, Two-, and Three-Dimensional Measurements of Childhood Brain Tumors J Natl Cancer Inst, September 19, 2001; 93(18): 1401 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Fountzilas, C. Papadimitriou, U. Dafni, D. Bafaloukos, D. Skarlos, L. A. Moulopoulos, E. Razis, H. P. Kalofonos, G. Aravantinos, E. Briassoulis, et al. Dose-Dense Sequential Chemotherapy With Epirubicin and Paclitaxel Versus the Combination, as First-Line Chemotherapy, in Advanced Breast Cancer: A Randomized Study Conducted by the Hellenic Cooperative Oncology Group J. Clin. Oncol., April 15, 2001; 19(8): 2232 - 2239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. C. Tempany and B. J. McNeil Advances in Biomedical Imaging JAMA, February 7, 2001; 285(5): 562 - 567. [Abstract] [Full Text] [PDF]
|
|